{
  "id": 11148774,
  "title": "How macrocyclic drugs are gaining momentum in the cardiometabolic disease space",
  "url": "https://urgent.news/2026/09/30/how-macrocyclic-drugs-are-gaining-momentum-in-the-cardiometabolic",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-30T13:00:00.000Z",
  "source": {
    "name": "Labiotech",
    "slug": "labiotech",
    "url": "https://www.labiotech.eu/in-depth/macrocyclic-drugs-cardiometabolic-diseases/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Discover biotech and big pharma’s emerging interest in developing macrocyclic drugs for cardiometabolic diseases. The post How macrocyclic drugs are gaining momentum in the cardiometabolic disease space appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}